Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cocrystal Pharma, Inc. COCP

Healthcare  —  Biotechnology
1.17 0.02 1.74% as of 25 Sep
Market cap
$22.2M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cocrystal Pharma, Inc. (COCP) Business Profile

Updated before January 2025

Company Overview

Cocrystal Pharma, Inc. (NASDAQ: COCP) is a biotechnology company specializing in the discovery and development of antiviral therapeutics. Founded in 2008, the company is headquartered in Bothell, Washington, with additional operations in Tucker, Georgia. Cocrystal Pharma was established with the mission of leveraging its proprietary structure-based drug design technology to develop novel antiviral drugs targeting serious and chronic viral diseases. The company’s leadership team includes experienced professionals in the pharmaceutical and biotechnology industries, with Dr. Sam Lee serving as President and Dr. James Martin as Chief Financial Officer. Their expertise in drug discovery and development has been instrumental in advancing the company’s pipeline of antiviral therapies.

Core Business Segments

Cocrystal Pharma focuses on the development of antiviral therapeutics targeting a range of viral infections. The company’s core business segments include:

Influenza Antiviral Programs

Cocrystal is developing antiviral compounds to treat influenza infections, including seasonal and pandemic strains. The company’s lead influenza program targets the replication machinery of the influenza virus, aiming to provide a broad-spectrum antiviral solution.

Hepatitis C Virus (HCV) Program

The company is advancing its HCV program with the goal of developing a highly effective treatment for hepatitis C. Cocrystal’s approach involves targeting the NS5B polymerase, a critical enzyme for viral replication, to inhibit the virus’s ability to reproduce.

COVID-19 Antiviral Programs

In response to the global COVID-19 pandemic, Cocrystal has expanded its pipeline to include antiviral compounds targeting SARS-CoV-2, the virus responsible for COVID-19. The company is leveraging its proprietary drug discovery platform to identify and develop inhibitors of key viral enzymes, such as the RNA-dependent RNA polymerase (RdRp) and main protease (Mpro).

Norovirus Program

Cocrystal is also working on antiviral therapies for norovirus, a leading cause of viral gastroenteritis. The company’s research focuses on developing inhibitors that target the viral replication process.

Business Model

Cocrystal Pharma’s business model is centered around its proprietary structure-based drug design technology, which enables the rapid identification and optimization of antiviral compounds. The company integrates its drug discovery platform with preclinical and clinical development to advance its pipeline of antiviral therapeutics. Revenue generation primarily comes from licensing agreements, collaborations with pharmaceutical companies, and potential future product sales. By partnering with larger pharmaceutical companies, Cocrystal aims to leverage their resources and expertise to bring its antiviral therapies to market.

Strategic Direction

Cocrystal Pharma is committed to advancing its pipeline of antiviral therapeutics and expanding its research into new viral targets. The company’s strategic priorities include:

  • Pipeline Expansion: Continuing to develop antiviral therapies for existing targets while exploring new viral diseases.
  • Partnerships and Collaborations: Establishing strategic partnerships with pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • Sustainability Goals: Incorporating sustainable practices into its operations, including minimizing environmental impact and promoting ethical research practices.
  • Global Reach: Expanding its presence in international markets to address unmet medical needs worldwide.

Competitive Landscape

Cocrystal Pharma operates in a competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Gilead Sciences: A leader in antiviral therapies, particularly for HIV and hepatitis C.
  • Roche: Known for its antiviral drugs targeting influenza and other viral infections.
  • Moderna and Pfizer: Major players in the development of COVID-19 vaccines and therapeutics.
  • Vir Biotechnology: Focused on developing treatments for infectious diseases, including COVID-19 and influenza.

Cocrystal differentiates itself through its proprietary drug discovery platform and focus on structure-based drug design, which enables the development of highly targeted antiviral therapies.

Risk Factors

Cocrystal Pharma faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The development and approval of new drugs are subject to stringent regulatory requirements, which can be time-consuming and costly.
  • Market Dependence: The company’s success depends on the commercial viability of its antiviral therapies, which may face competition from existing treatments.
  • Supply Chain Disruptions: The global supply chain for pharmaceutical ingredients and materials can be affected by geopolitical events, natural disasters, or pandemics.
  • Clinical Trial Risks: The success of Cocrystal’s drug candidates depends on the outcomes of clinical trials, which may not always yield favorable results.

Recent Developments

Cocrystal Pharma has made significant progress in advancing its antiviral pipeline. Recent developments include:

  • COVID-19 Programs: The company has identified promising lead compounds targeting SARS-CoV-2 and is advancing them through preclinical development.
  • Partnerships: Cocrystal has entered into collaborations with leading pharmaceutical companies to accelerate the development of its antiviral therapies.
  • Funding: The company has secured additional funding to support its research and development activities, ensuring the continued advancement of its pipeline.

Investment Considerations

Investors considering Cocrystal Pharma should weigh the following strengths and risks:

Strengths

  • Proprietary drug discovery platform with a focus on structure-based drug design.
  • Diverse pipeline targeting multiple viral diseases, including COVID-19, influenza, and hepatitis C.
  • Experienced leadership team with a track record of success in drug development.
  • Strategic partnerships with pharmaceutical companies to accelerate development and commercialization.

Risks

  • Dependence on the success of clinical trials and regulatory approvals.
  • Competition from established pharmaceutical companies and emerging biotech firms.
  • Potential delays in product development due to supply chain disruptions or other external factors.

Conclusion

Cocrystal Pharma, Inc. is a promising biotechnology company with a strong focus on developing antiviral therapeutics for serious and chronic viral diseases. Leveraging its proprietary drug discovery platform, the company has built a diverse pipeline targeting high-priority viral infections, including COVID-19, influenza, and hepatitis C. While the company faces risks associated with drug development and market competition, its strategic partnerships and experienced leadership position it well for future growth. As Cocrystal continues to advance its pipeline and expand its global reach, it remains a compelling investment opportunity in the biotechnology sector.